AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $8.30, but opened at $9.13. AIM ImmunoTech shares last traded at $8.99, with a volume of 68,101 shares trading hands.
AIM ImmunoTech Stock Performance
The company's fifty day simple moving average is $9.13 and its two-hundred day simple moving average is $14.26. The company has a market capitalization of $651.33 million, a price-to-earnings ratio of -19.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75.
About AIM ImmunoTech
(
Get Free Report)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AIM ImmunoTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AIM ImmunoTech wasn't on the list.
While AIM ImmunoTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
